Previous close | 417.32 |
Open | 419.48 |
Bid | 418.04 x 100 |
Ask | 418.55 x 100 |
Day's range | 415.06 - 420.67 |
52-week range | 312.10 - 448.40 |
Volume | |
Avg. volume | 1,321,181 |
Market cap | 107.975B |
Beta (5Y monthly) | 0.35 |
PE ratio (TTM) | 30.12 |
EPS (TTM) | 13.88 |
Earnings date | 29 Apr 2024 - 03 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 464.98 |
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.